Sifalimumab
Sifalimumab Basic information
- Product Name:
- Sifalimumab
- Synonyms:
-
- Sifalimumab
- Research Grade Sifalimumab(DHB94501)
- Sifalimumab (anti-IFNa1)
- MDX-1103|||MEDI-545
- Research Grade Sifalimumab
- CAS:
- 1006877-41-3
- MW:
- 0
- Mol File:
- Mol File
Sifalimumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Sifalimumab Usage And Synthesis
Uses
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research[1][2].
in vivo
Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration[2].
| Animal Model: | Wild-type male BALB/c mice[2] |
| Dosage: | 30 mg/kg and 3 μg/g |
| Administration: | Subcutaneous injection; 30 mg/kg and 3 μg/g |
| Result: | Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05). Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration. Attenuated the CD45 increase (P<0.05). |
References
[1] Merrill JT, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905-13. DOI:10.1136/ard.2010.144485
[2] La Maestra S, et al. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation. Drug Deliv Transl Res. 2018 Oct;8(5):1345-1354. DOI:10.1007/s13346-018-0535-3
SifalimumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com